[go: up one dir, main page]

PE20091331A1 - Composiciones farmaceuticas que comprenden polimeros de amina reticulada - Google Patents

Composiciones farmaceuticas que comprenden polimeros de amina reticulada

Info

Publication number
PE20091331A1
PE20091331A1 PE2008002075A PE2008002075A PE20091331A1 PE 20091331 A1 PE20091331 A1 PE 20091331A1 PE 2008002075 A PE2008002075 A PE 2008002075A PE 2008002075 A PE2008002075 A PE 2008002075A PE 20091331 A1 PE20091331 A1 PE 20091331A1
Authority
PE
Peru
Prior art keywords
pharmaceutical compositions
compositions including
amine polymers
reticulated
including crosslink
Prior art date
Application number
PE2008002075A
Other languages
English (en)
Inventor
David J Harris
Steven C Polomoscanik
Adnan Salameh
Bruce Shutts
Richard Silva
Pradeep K Dhal
Lynne Sole
Stephen Randall Holmes-Farley
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of PE20091331A1 publication Critical patent/PE20091331A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J41/00—Anion exchange; Use of material as anion exchangers; Treatment of material for improving the anion exchange properties
    • B01J41/08—Use of material as anion exchangers; Treatment of material for improving the anion exchange properties
    • B01J41/12—Macromolecular compounds
    • B01J41/14—Macromolecular compounds obtained by reactions only involving unsaturated carbon-to-carbon bonds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

REFERIDA A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE UN POLIMERO DE AMINA RETICULADA QUE COMPRENDE UNIDADES DE REPETICION REPRESENTADAS POR LAS FORMULAS I Y/O II Y UN AGENTE RETICULANTE O UN RESIDUO DEL MISMO, DONDE m ES UN ENTERO DE 0 A 2, n ES UN NUMERO ENTERO, R1, R2, Y R3 SON H, ALQUILO C1-C6, ALQUILAMINO C1-C6, X- ES UN CONTRAION TAL COMO CARBONATO, BICARBONATO, CLORHIDRATO, ENTRE OTROS. EL POLIMERO DE AMINA RETICULADA TIENE UN VALOR DE ALANINA DE ENTRE 0,6 A 0,75 ppm, UN pH de ENTRE 9,3 A 9,7 Y UN PORCENTAJE DE OLIGOMEROS SOLUBLES MENOR A 0.1%. TAMBIEN ESTA REFERIDA A UN COMPRIMIDO QUE CONTIENE LA COMPOSICION Y A UN METODO DE PREPARACION
PE2008002075A 2007-12-14 2008-12-12 Composiciones farmaceuticas que comprenden polimeros de amina reticulada PE20091331A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US601907P 2007-12-14 2007-12-14

Publications (1)

Publication Number Publication Date
PE20091331A1 true PE20091331A1 (es) 2009-09-18

Family

ID=40753579

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008002075A PE20091331A1 (es) 2007-12-14 2008-12-12 Composiciones farmaceuticas que comprenden polimeros de amina reticulada

Country Status (9)

Country Link
US (4) US20090155368A1 (es)
EP (1) EP2222313A4 (es)
JP (1) JP2011506448A (es)
AR (1) AR072652A1 (es)
PA (1) PA8807201A1 (es)
PE (1) PE20091331A1 (es)
TW (1) TW200930384A (es)
UY (1) UY31530A (es)
WO (1) WO2009078956A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110142952A1 (en) * 2008-06-20 2011-06-16 Harris David J Pharmaceutical Compositions
WO2013064193A1 (en) * 2011-11-04 2013-05-10 Synthon Bv Pharmaceutical compositions comprising sevelamer
EP2791183A1 (en) * 2011-12-13 2014-10-22 Synthon BV Preparation of sevelamer with reduced content of allylamine
WO2013087237A1 (en) * 2011-12-13 2013-06-20 Synthon Bv Purification of sevelamer and related polyallylamines
CN102895204B (zh) * 2012-11-08 2014-12-31 南京生命能科技开发有限公司 一种用于制备片剂的碳酸司维拉姆原料药及其制备方法和应用
CN103864972A (zh) * 2012-12-10 2014-06-18 天津泰普药品科技发展有限公司 一种碳酸司维拉姆的制备方法
US9566299B2 (en) * 2013-02-08 2017-02-14 Wockhardt Limited Oral pharmaceutical composition of aliphatic amine polymer or salts thereof
ES2646271T3 (es) 2013-06-05 2017-12-13 Tricida Inc. Polímeros de unión de protones para la administración oral
MD3229816T2 (ro) 2014-12-10 2020-07-31 Tricida Inc Polimeri de legare a protonilor pentru administrare orală
MA41202A (fr) * 2014-12-18 2017-10-24 Genzyme Corp Copolymères polydiallymine réticulé pour le traitement du diabète de type 2
IL262660B2 (en) 2016-05-06 2024-04-01 Tricida Inc Compositions for and method of treating acid-base disorders
CA3039062A1 (en) * 2016-10-20 2018-04-26 Colgate-Palmolive Company Antimicrobial compositions for oral care or cleansing, and methods for anti-attachment polymers and coatings
KR101853260B1 (ko) * 2016-11-29 2018-06-14 주식회사 퍼슨 세벨라머 카보네이트의 제조방법
AU2017388956A1 (en) 2016-12-28 2019-07-11 Fujifilm Corporation Emulsion of nitrogen atom-containing polymer or salt thereof, production method therefor, and production method for particles
CN111246857A (zh) * 2017-10-16 2020-06-05 富士胶片株式会社 高磷血症治疗剂及粒子
TW201922267A (zh) 2017-10-16 2019-06-16 日商富士軟片股份有限公司 高磷血症治療劑
CA3080651A1 (en) 2017-11-03 2019-05-09 Tricida, Inc. Compositions for and method of treating acid-base disorders
CN109125273B (zh) * 2018-09-28 2020-10-09 北京市中关村医院 一种磷结合剂及其制备方法和用途
CN112972407A (zh) * 2019-12-18 2021-06-18 南京恒生制药有限公司 一种碳酸司维拉姆片剂组合物及其制备方法
WO2024246913A1 (en) * 2023-05-31 2024-12-05 Ramot At Tel-Aviv University Ltd. Core-sheath microstructures, process of preparing same and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW474813B (en) * 1994-06-10 2002-02-01 Geltex Pharma Inc Alkylated composition for removing bile salts from a patient
US6423754B1 (en) * 1997-06-18 2002-07-23 Geltex Pharmaceuticals, Inc. Method for treating hypercholesterolemia with polyallylamine polymers
TW568788B (en) * 1998-10-12 2004-01-01 Chugai Pharmaceutical Co Ltd Polymer combining with phosphoric acid and preparation containing the same
US7608674B2 (en) * 2003-11-03 2009-10-27 Ilypsa, Inc. Pharmaceutical compositions comprising cross-linked small molecule amine polymers
EP1924246B1 (en) * 2005-09-15 2015-10-21 Genzyme Corporation Sachet formulation for amine polymers

Also Published As

Publication number Publication date
PA8807201A1 (es) 2009-07-23
US20140322319A1 (en) 2014-10-30
EP2222313A1 (en) 2010-09-01
UY31530A (es) 2009-12-14
US20090155368A1 (en) 2009-06-18
WO2009078956A1 (en) 2009-06-25
AR072652A1 (es) 2010-09-15
EP2222313A4 (en) 2011-02-16
TW200930384A (en) 2009-07-16
JP2011506448A (ja) 2011-03-03
US20160158275A1 (en) 2016-06-09
US20190240252A1 (en) 2019-08-08

Similar Documents

Publication Publication Date Title
PE20091331A1 (es) Composiciones farmaceuticas que comprenden polimeros de amina reticulada
BR112015032062A8 (pt) aduto de aceptor de michael contendo enxofre, composição, aduto de aceptor de michael contendo enxofre terminado por hidroxila e aduto contendo enxofre terminado por amina
MX2020006014A (es) Compuestos de diazaindol.
PE20181045A1 (es) Compuestos utiles como inmunomoduladores
PH12018502515B1 (en) New piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
PH12017501539A1 (en) Disacetoxytubulysin h and analogs thereof
CL2004000917A1 (es) Compuestos derivados de tiazol; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de enfermedades mediadas por 3-cinasa de dosfatidilnositol tal como enfermedades respiratorias, alergias, artritis reumatoide, osteoa
AR076421A1 (es) Eficiencia mejorada de composiciones de pantalla solar
MX389802B (es) Composiciones enriquecidas estereoquimicamente para administracion de acidos nucleicos.
SE0202133D0 (sv) Novel compounds
PE20080688A1 (es) Derivados de n-(amino-heteroaril)-1h-indol-2-carboxamidas como antagonistas de trpv1 y su preparacion
UY27984A1 (es) Composicion farmaceutica para el suministro por via topica de meloxicam
UY31712A1 (es) Nuevos derivados de diosmetina, su procedimiento de preparacion y las composiciones farmacéuticas que los contienen
ECSP055710A (es) Composición antihelmíntica e inyectable mejoradora de crecimiento
TW200704764A (en) Stabilized electrochromic media
AR065016A1 (es) Composiciones polimericas, metodos para fabricar las mismas y articulos preparados de las mismas
AR092806A1 (es) Formulacion concentrada liquida que contiene un insecticida de piripiropeno i
PA8855001A1 (es) Monocarbamas
AR108558A2 (es) Método para preparar ácido (+)-1,4-dihidro-7-[(3s,4s)-3-metoxi-4-(metilamino)-1-pirrolidinil]-4-oxo-1-(2-tiazolil)-1,8-naftiridin-3-carboxílico
PA8768301A1 (es) Nuevos derivados tricíclicos, su procedimiento de preparación y las composiciones farmacéuticas que lo contienen
CL2021000421A1 (es) Nuevo derivado de amina heterocíclico y composición farmacéutica que lo comprende.
PH12021550439A1 (en) O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors
PE20171510A1 (es) Copolimeros de polidialilamina reticulados para el tratamiento de la diabetes de tipo 2
UY38567A (es) Inhibidores de o-glucoproteína-2-acetamido-2-desoxi-3-d-glucopiranosidasa de éter bicíclico
SG165381A1 (en) Novel benzimidazole and benzothiazole derivatives, method for preparing same, use thereof as drugs, pharmaceutical compositions and novel use in particular as c-met inhibitors

Legal Events

Date Code Title Description
FD Application declared void or lapsed